Fukagawa M, Hamada Y, Nakanishi S, Tanaka M (2006) The kidney and bone metabolism: nephrologists’ point of view. J Bone Miner Metab 24:434–438

Article  CAS  PubMed  Google Scholar 

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of Vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435

Article  CAS  PubMed  Google Scholar 

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) (2009) (in eng). Kidney Int Suppl:S1–130

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215

Article  CAS  PubMed  Google Scholar 

Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T (2010) Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78:975–980

Article  CAS  PubMed  Google Scholar 

Komaba H, Fukagawa M (2010) FGF23–parathyroid interaction: implications in chronic kidney disease. Kidney Int 77:292–298

Article  CAS  PubMed  Google Scholar 

Kawabata C, Komaba H, Ishida H, Nakagawa Y, Hamano N, Koizumi M, Kanai G, Wada T, Nakamura M, Fukagawa M (2020) Changes in fibroblast growth factor 23 and soluble klotho levels after hemodialysis initiation. Kidney Med 2:59–67

Article  PubMed  Google Scholar 

Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR (2006) Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70:351–357

Article  CAS  PubMed  Google Scholar 

Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H (1997) Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism (in eng). Semin Surg Oncol 13:78–86

Article  CAS  PubMed  Google Scholar 

Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drüeke TB (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51:328–336

Article  CAS  PubMed  Google Scholar 

Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436–1443

Article  CAS  PubMed  PubMed Central  Google Scholar 

Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K-I, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77:232–238

Article  CAS  PubMed  Google Scholar 

Komaba H (2023) Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects. Clin Exp Nephrol 27:395–401

Article  PubMed  PubMed Central  Google Scholar 

Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara Y (2013) Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 17:221–228

Article  CAS  PubMed  Google Scholar 

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218

Article  CAS  PubMed  Google Scholar 

Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519–530

Article  CAS  PubMed  Google Scholar 

EVOLVE Trial Investigators (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494

Article  Google Scholar 

Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C (2004) Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66:2010–2016

Article  PubMed  Google Scholar 

Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M (2015) Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88:350–359

Article  PubMed  Google Scholar 

Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, Nitta K, Fukagawa M (2022) Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocr Metab 107:2016–2025

Article  PubMed  Google Scholar 

Lopes MB, Karaboyas A, Bieber B, Pisoni RL, Walpen S, Fukagawa M, Christensson A, Evenepoel P, Pegoraro M, Robinson BM, Pecoits-Filho R (2020) Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS. Nephrol Dial Transplant 35:1794–1801

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:e10–e17

Article  CAS  PubMed  Google Scholar 

Isaka Y, Hamano T, Fujii H, Tsujimoto Y, Koiwa F, Sakaguchi Y, Tanaka R, Tomiyama N, Tatsugami F, Teramukai S (2021) Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol 32:723–735

Article  PubMed  PubMed Central  Google Scholar 

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945–1953

Article  CAS  PubMed  Google Scholar 

Hasegawa T, Tokunaga S, Yamamoto T, Sakai M, Hongo H, Kawata T, Amizuka N (2023) Evocalcet rescues secondary hyperparathyroidism-driven cortical porosity in CKD male rats. Endocrinology 164:1–17

Article  CAS  Google Scholar 

Andress DL (2008) Adynamic bone in patients with chronic kidney disease. Kidney Int 73:1345–1354

Article  CAS  PubMed  Google Scholar 

Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358–1366

Article  CAS  PubMed  Google Scholar 

Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Suppl 3:446–450

Article  CAS  Google Scholar 

Moe SM (2017) Renal osteodystrophy or kidney-induced osteoporosis? Curr Osteoporos Rep 15:194–197

Article  PubMed  PubMed Central  Google Scholar 

Iwasaki Y, Kazama JJ, Yamato H, Matsugaki A, Nakano T, Fukagawa M (2015) Altered material properties are responsible for bone fragility in rats with chronic kidney injury. Bone 81:247–254

Article  PubMed  Google Scholar 

Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R (2008) Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22:2465–2475

Article  CAS  PubMed